The Science Behind Restore Gold™
Restore Gold™ has rapidly become the go-to for hundreds of Parkinson’s Disease sufferers. Seeing positive feedback in more than 80% of cases, the capsules contain seven specific ingredients that have brought impressive relief to some with PD. Utilizing recent published research, the capsules are one of a kind. But what is the science behind Restore Gold™?
A revolutionary product that’s made up of large dosages of seven specific ingredients that have been supported by the latest Parkinson’s research, the Restore Gold™ capsules have provided results for sufferers in as little as three months.
Thanks to continued research, experts now know that a primary cause of Parkinson’s is mitochondrial dysfunction, with secondary causes being neural oxidation, neural inflammation, and alpha-synuclein aggregation all causing a toxic overload on surrounding neural cells in the substantia nigra.
One of the key ingredients in Restore Gold™ is n-acetyl-cysteine (NAC), with 400mg per serving. Having recently demonstrated the ability to increase dopamine binding by 9% and improve UPDRS score results by 13% in clinical trials, this ingredient has impressed Parkinson’s researchers ever since.
Another key ingredient in Restore Gold™ is green tea leaf (EGCg). Sitting at 200mg per serving, the extract is designed to help neutralize stress-induced free radicals and inflammation. Extensive research on the effects of green tea has suggested that this natural product, which is used in so many cultures, in so many different ways, shows that the neuroprotective/neurodegenerative effects of green tea catechins not only act as antioxidants metal chelators, but also as modulators of intracellular neuronal signaling and metabolism, cell survival/death genes, and mitochondrial function.
L-tyrosine has been a long-term interest in Parkinson’s research. With fewer side effects than other treatments, L-tyrosine significantly increased CSF tyrosine levels in groups of patients, indicating that L-tyrosine administration can increase dopamine turnover in patients with disorders, such as Parkinson’s.
Parkinson disease has been associated with systemic defects in mitochondrial function for years and is considered the number one problem in causing Parkinson’s disease to progress. And the best of these characterized is reduced activity of complex I of the electron transport chain. After many years of research, it became clear that some autosomal, recessive forms of Parkinson’s are caused by mutations in genes that affect mitochondrial function or quality control. As perhaps the most important ingredient, TUDCA (Tauroursodeoxycholic Acid) has been has been added to Restore Gold™ capsules due to the research suggesting it can actually restore mitochondrial function.
There are of course three more ingredients in Restore Gold™, each added due to their positive support in Parkinson’s research, Grape Seed Extract, Acetyl L-Carnitine, and Alpha Lipoic Acid (ALA) are also included at specific dosages.
Find out more about Restore Gold™ by contacting We Have Parkinson’s.
Promising Links Found between Different Causes of Parkinson’s
Scientific American: September 8, 2016
The Role of Oxidative Stress in Parkinson’s Disease
J Parkinsons Dis. Author manuscript; available in PMC 2014 Aug 18.
Parkinson’s disease and alpha synuclein: is Parkinson’s disease a prion-like disorder?
Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373.
L-tyrosine: a long term treatment of Parkinson’s disease.
C R Acad Sci III. 1989;309(2):43-7.
Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson’s disease.
Life Sci. 1982 Mar 8;30(10):827-32.
Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson’s disease
Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson’s Disease: Modulation of Mitochondrial Perturbations
Molecular Neurobiology, March 2016, Volume 53, Issue 2, pp 810–817
Bile acids: regulation of apoptosis by ursodeoxycholic acid
September 2009 The Journal of Lipid Research, 50, 1721-1734.
Tauroursodeoxycholic acid prevents MPTP-induced dopaminergic cell death in a mouse model of Parkinson’s disease.
Mol Neurobiol. 2012 Oct;46(2):475-86. doi: 10.1007/s12035-012-8295-4. Epub 2012 Jul 8.
Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans.
J Biol Chem. 2005 Dec 30;280(52):42655-68. Epub 2005 Oct 19.
Fruit flies, bile acids, and Parkinson disease
Published online before print August 7, 2015, doi: http:/?/?dx.?doi.?org/?10.?1212/?WNL.?0000000000001912 Neurology 10.1212/WNL.0000000000001912
Neuroprotective effects of anthocyanin- and proanthocyanidin-rich extracts in cellular models of Parkinson?s disease.
Brain Res. 2014 Mar 25;1555:60-77. doi: 10.1016/j.brainres.2014.01.047. Epub 2014 Feb 3.
Gallic acid is the major component of grape seed extract that inhibits amyloid fibril formation.
Bioorg Med Chem Lett. 2013 Dec 1;23(23):6336-40. doi: 10.1016/j.bmcl.2013.09.071. Epub 2013 Oct 1.
Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding.
Expert Rev Proteomics. 2010 Aug;7(4):579-89. doi: 10.1586/epr.10.69.
Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention.
Toxicology. 2000 Aug 7;148(2-3):187-97.
Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases.
J Alzheimers Dis. 2011;25(2):187-208. doi: 10.3233/JAD-2011-101803.
Inhibition of inducible nitric oxide synthase expression and cell death by (-)-epigallocatechin-3-gallate, a green tea catechin, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease.
J Clin Neurosci. 2010 Sep;17(9):1165-8. doi: 10.1016/j.jocn.2010.01.042. Epub 2010 Jun 11.
[Review on the neuroprotective effects of green tea polyphenols for the treatment of neurodegenerative diseases].
Wei Sheng Yan Jiu. 2010 Jan;39(1):123-6.
A pro-drug of the green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) prevents differentiated SH-SY5Y cells from toxicity induced by 6-hydroxydopamine.
Neurosci Lett. 2010 Jan 29;469(3):360-4. doi: 10.1016/j.neulet.2009.12.028. Epub 2009 Dec 18.
Effects of epigallocatechin gallate on rotenone-injured murine brain cultures.
J Neural Transm (Vienna). 2010 Jan;117(1):5-12. doi: 10.1007/s00702-009-0284-z. Epub 2009 Aug 26.
Natural antioxidants protect neurons in Alzheimer’s disease and Parkinson’s disease.
Neurochem Res. 2009 Apr;34(4):630-8. doi: 10.1007/s11064-008-9900-9. Epub 2009 Jan 6.
Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases.
CNS Neurosci Ther. 2008 Winter;14(4):352-65. doi: 10.1111/j.1755-5949.2008.00060.x.
Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG).
J Alzheimers Dis. 2008 Oct;15(2):211-22.
Neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) on paraquat-induced apoptosis in PC12 cells.
Cell Biol Int. 2008 Jan;32(1):22-30. Epub 2007 Sep 1.
Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson’s disease through inhibition of ROS-NO pathway.
Biol Psychiatry. 2007 Dec 15;62(12):1353-62. Epub 2007 Jul 12.
N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson’s Disease: Preliminary Clinical and Cell Line Data.
PLoS One. 2016 Jun 16;11(6):e0157602. doi: 10.1371/journal.pone.0157602. eCollection 2016.
Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinson’s disease.
Parkinsonism Relat Disord. 2015 May;21(5):500-3. doi: 10.1016/j.parkreldis.2015.02.020. Epub 2015 Feb 28.
N-acetylcysteine prevents rotenone-induced Parkinson’s disease in rat: An investigation into the interaction of parkin and Drp1 proteins.
Brain Res Bull. 2015 Apr;113:34-40. doi: 10.1016/j.brainresbull.2015.02.007. Epub 2015 Feb 28.
Glutathione metabolism and Parkinson’s disease.
Free Radic Biol Med. 2013 Sep;62:13-25. doi: 10.1016/j.freeradbiomed.2013.05.001. Epub 2013 May 8.
N-acetylcysteine protects against apoptosis through modulation of group I metabotropic glutamate receptor activity.
PLoS One. 2012;7(3):e32503. doi: 10.1371/journal.pone.0032503. Epub 2012 Mar 19.
Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice.
PLoS One. 2010 Aug 23;5(8):e12333. doi: 10.1371/journal.pone.0012333.
Natural molecule NAC could benefit patients with Parkinson’s disease
News Medical Net 2016
Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson’s disease.
J Cell Mol Med. 2010 Jan;14(1-2):215-25. doi: 10.1111/j.1582-4934.2008.00390.x.
Clinical pharmacodynamics of acetyl-L-carnitine in patients with Parkinson’s disease.
Int J Clin Pharmacol Res. 1990;10(1-2):139-43.
Acetyl-L-carnitine and alpha-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson’s disease therapy.
Pharmacol Biochem Behav. 2012 Jan;100(3):347-60. doi: 10.1016/j.pbb.2011.09.002. Epub 2011 Sep 21.
Management of the aging risk factor for Parkinson’s disease.
Neurobiol Aging. 2014 Apr;35(4):847-57. doi: 10.1016/j.neurobiolaging.2013.10.073. Epub 2013 Oct 10.
Behavioral and neurochemical effects of alpha-lipoic Acid in the model of Parkinson’s disease induced by unilateral stereotaxic injection of 6-ohda in rat.
Evid Based Complement Alternat Med. 2013;2013:571378. doi: 10.1155/2013/571378. Epub 2013 Aug 19.
Alpha-lipoic acid protects dopaminergic neurons against MPP+-induced apoptosis by attenuating reactive oxygen species formation.
Int J Mol Med. 2013 Jul;32(1):108-14. doi: 10.3892/ijmm.2013.1361. Epub 2013 Apr 24.
Alpha-lipoic acid protects against 6-hydroxydopamine-induced neurotoxicity in a rat model of hemi-parkinsonism.
Brain Res. 2013 Apr 10;1505:68-74. doi: 10.1016/j.brainres.2013.01.054. Epub 2013 Feb 13.
Acetyl-L-carnitine and ?-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson’s disease therapy.
Pharmacol Biochem Behav. 2012 Jan;100(3):347-60. doi: 10.1016/j.pbb.2011.09.002. Epub 2011 Sep 21.
Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of alpha-lipoic acid against rotenone-induced parkinsonism and L-dopa toxicity.
Neurosci Res. 2011 Dec;71(4):387-95. doi: 10.1016/j.neures.2011.08.008. Epub 2011 Aug 26.
The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of Parkinson’s disease: a review.
Int J Neurosci. 2011 Feb;121(2):51-7. doi: 10.3109/00207454.2010.535934. Epub 2010 Dec 2.
Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson’s disease: protection by alpha-lipoic acid.
FASEB J. 2007 Jul;21(9):2226-36. Epub 2007 Mar 16.
L-dopa- and dopamine-(R)-alpha-lipoic acid conjugates as multifunctional codrugs with antioxidant properties.
J Med Chem. 2006 Feb 23;49(4):1486-93.
Restore Gold™ is Changing Lives